Make more lentivirus and make it right the first time

Lentiviral vectors (LVs) are increasingly used in gene-modified cell therapy manufacturing due to their capacity for large genetic payloads, stable gene delivery, and low immuno­genicity. However, their manufacturing presents several challenges, including safety, performance, and purification stability. This article examines key hurdles such as achieving accurate vector measurements, maximizing viral titers, and optimizing purification processes. It highlights advances in LV production and explores the significance of design of experiments (DOE) in optimizing transfection processes and the importance of scalability in developing robust manufacturing strategies.